Abstract: An aqueous leave-on hair conditioning composition which comprises:

Abstract: The present invention provides an aftershave composition comprising, by weight, 9% to 94%, preferably 15% to 85%, most preferably 25% to 55%, water, 5% to 90%, preferably 10% to 80%, most preferably 40% to 70%, ethanol, 0.25% to 6%, preferably 1% to 5%, fragrance, 0.25% to 5%, preferably 1% to 4%, surfactant to solubilize or emulsify the fragrance, and 0.05% to 1.5%, preferably 0.1% to 0.6%, phosphatidyl choline. Preferably, the composition will be a clear solution or microemulsion having a clarity better than 100 NTU and a viscosity less than 200 mPas. The foregoing composition provides skin moisturization and reduced irritation without other undesirable aesthetic attributes such as stickiness or oiliness. The present invention also embraces a method of reducing irritation of human skin caused by shaving comprising topically applying to human skin after shaving an aftershave composition as described above.

Abstract: A composition comprising a chlorinating agent; a nearly insoluble di- or tri-valent metal salt which is an oxide, a hydroxide, a carbonate, or mixture thereof; and the composition has a pH of less than about 10.5 when in use.

Abstract: Compositions which contain an acid and an organic polymer that has carboxyl and/or hydroxyl groups, and which are suitable in particular or the desensitization of teeth.

Abstract: A sterilizing disinfectant and an antimicrobial agent comprising a cationic polymer represented by general formula [1] and an antimicrobial material using a cationic polymer represented by general formula [1].

Abstract: Improved molecularly imprinted polymers (MIPs) with both higher and more specific binding capacity for particular bile acids and/or salts, including the synthesis of such MIPs, the compounds themselves, and specific applications thereof. As an example of a particularly preferred specific application of these compounds, the present invention encompasses the use of the MIPs as sequestrants in the gastrointestinal tract, particularly in order to bind and therefore remove toxins from the gastrointestinal tract. In addition, the present invention is also useful for treatment of various diseases which are related to, and/or characterized by, an effect of bile acids and salts, such as atherosclerosis, liver disease and various diseases of the gastrointestinal tract. The MIP compounds of the present invention are also useful for combination therapy with other medications and for diagnosis and monitoring of diseases.

Abstract: Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.

Abstract: The present invention relates to compositions and their methods of manufacture and use which are effective for delivering a homogeneous distribution of a boron containing active ingredient to a tree or tree derived substrate for the purpose of preventing or eradicating an infestation and/or for imparting flame retardency thereto.

Abstract: Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.

Abstract: The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of granulocyte colony stimulating factor (G-CSF) to result in granulocyte colony stimulating factor (G-CSF) proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.

Abstract: The present invention provides a method of treating a condition or disease characterized by an excess of one or more androgens, the method comprising administering an effective amount of MIS protein or nucleic acid encoding MIS to a patient. The present invention also provides a method of decreasing the level of one or more androgens to a level below the normal level, the method comprising administering an effective amount of MIS protein or nucleic acid encoding MIS to a patient. The methods of the present invention are particularly well-suited for the treatment of prostatic cancer, polycystic ovarian disease, benign prostatic hypertrophy, and precocious puberty.

Abstract: Methods for inhibiting angiogenesis using gene therapy are disclosed. Genes encoding PLGF or VEGF-B are delivered to cells e.g., tumor cells, which express VEGF, such that heterodimers of PLGF/VEGF and/or VEGF-B/VEGF are formed within the cells, preferably at a greater ratio than homodimers of VEGF/VEGF. The heterodimers have reduced angiogenic activity compared to VEGF homodimers.

Abstract: The present invention provides recombinant adeno-associated virus (rAAV) vectors comprising a heterologous nucleotide sequence encoding factor VIII (factor VIII). In preferred embodiments, the factor VIII is a B-domain deleted factor VIII. Also provided are methods of producing a high titer stock of the inventive rAAV/factor VIII vectors. Another aspect of the invention is a method of delivering a nucleotide sequence encoding factor VIII to a cell, preferably for subsequent administration to a subject. The present invention further provides methods of administering rAAV/factor VIII to a subject, e.g., for the treatment of hemophilia. The rAAV vector may be administered by any route, but is preferably administered to the liver.

Abstract: The present invention is directed to implantable, biocompatible scaffolds containing a biocompatible, porous, polymeric matrix, a biocompatible, porous, fibrous mat encapsulated by and disposed within said polymeric matrix, and a plurality of mammalian cells seeded within said tissue scaffold. The invention also is directed to methods of treating disease or structural defects in a mammal utilizing the scaffolds of the invention.

Abstract: A method of treating chronic HCV infections is disclosed. The method involves the optional treatment of a patient with interferon alpha and the treatment of a patient's blood with a psoralen compound followed by ultra violet light-activation of the psoralen compound. The blood treated as such is returned to the patient in a process known as extracorporeal photopheresis.

Abstract: A method for obtaining lineage committed human cells imbued with enhanced proliferative potential, biological function, or both, comprising culturing lineage committed human cells under physiologically acceptable liquid culture conditions, where the liquid culture medium is replaced at a rate and for a time sufficient to obtain the human lineage committed cells imbued with enhanced proliferative potential, biological function, or both; and isolating the cultured cells.

Abstract: The present invention provides methods, as well as compositions related thereto, for the efficient transduction of cells using viral vectors. The efficiency of transduction is increased by contacting the cell to be transduced with one or more molecules that bind the cell surface. Contact with a cell surface binding molecule may occur before, after, or simultaneously with contact between the viral vector and the cell. The transduced vectors may be constructed to express a gene of interest, permitting the transduced cells to be used as therapeutic and prophylactic agents.

Abstract: The invention includes a method of treating gastrointestinal diseases associated with species of genus Clostridium such as clostridium deficit in human patients with gastrointestinal disorders having an etiological component such as a microbial agent producing a toxin where treated with an antimicrobial composition an amount effective to inhibit or eliminate the microbial agent. The antimicrobial composition in a form of probiotic mixture can be administrated alone or in combination with an antimicrobial agent, such as a bacteriophage which is specific for a bacterium producing toxin or antibiotics which are then used to eliminate or inhibit the clostridial species overgrown in a patient's gastrointestinal tract. Disorders that can be treated by the method of the invention include diarrhea or inflammatory bowel diseases such as colitis or Crohn's disease.

Abstract: The invention relates to a probiotic combination comprising different combinations of lactobacilli. propionic acid bacteria and/or bifidobacteria. The probiotics are preferably combined with a suitable prebiotic to form a synbiotic. The combination of the invention can be consumed as such or combined with a suitable foodstuff or pharmaceutical product, and it is therapeutically useful for example for stimulating the immune system and for general health improvement.

Abstract: A hydrogel patch is disclosed which is comprised of a polymeric material which forms a gel with water with the material being present in an amount of about 0.5% to 40% by weight based on the weight of the patch. Electrical conductively of the water is increased by the addition of an electrolyte. The patch comprises an enzyme which is capable of catalyzing a reaction with a biomedically important molecule such as glucose. Glucose drawn into the patch undergoes a reaction with the aid of the enzyme and the hydrogen peroxide released flows through the electrically conductivity of the water and may react at an electrode surface to generate a signal related to the amount of glucose entering the patch. The patch is also preferably comprised of a buffer which maintains the pH of the patch in the range of from about 3 to 9, and may be further comprised of a cross-linking agent, a biocide, a humectant, and a surfactant. The patch is preferably in the form of a thin (5 &mgr;m-50 mils), flat circular disc (0.

Abstract: The present invention relates to the identification and use of a family of human complement C3-degrading proteinases expressed by S. pneumoniae. The proteinase has a molecular weight of about 24 kD to about 34 kD as determined on a 10% SDS polyacrylamide gel. A preferred proteinase of this invention includes the amino acid sequence of SEQ ID NO: 2.

Abstract: A novel gene (designated 151P3D4) and its encoded protein, and variants thereof, are described wherein 151P3D4 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 151P3D4 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 151P3D4 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 151P3D4 can be used in active or passive immunization.

Abstract: The invention provides a method for removing bacteria From antibody-containing milk that has been expressed from a bovid animal producing antibodies by sensitization with one or more antigens selected from among pathogens and their metabolic products, characterized in that defatting treatment is followed by filtration using a microfilter comprising a support and a filter membrane formed from ceramic fine particles, having filtration pores and a thickness between 40 to 150 &mgr;m.

Abstract: Ligation of the Fc&ggr; receptor type I (Fc&ggr;RI) on IL-10-producing cells leads to a selective upregulation of IL-10 production, which in turn induces a marked suppression of IL-12 biosynthesis by IL-12-producing cells, particularly macrophages. The ligation of the Fc&ggr;RI receptor thus downmodulates IL-12 production via a mechanism that is dependent on macrophage-derived IL-10. Agents for ligating Fc&ggr;RI comprise, for example, multivalent antibodies which bind the Fc&ggr;RI receptor, immune complexes comprising antibodies which contain the Fc region of IgG, and IgG multimers, preferably IgG dimers and trimers. The ligating agent may be administered to therapeutically inhibit proinflammatory immune responses. In particular, the ligating agent may be administered to treat or prevent endotoxic shock associated with bacterial endotoxemia, and to treating autoimmune disorders.

Abstract: There is disclosed a method and pharmaceutical composition for treating or mitigating the side effects of cytotoxic cancer therapy for carcinoma-type cancers tumors including administering a thiol-based chemoproctectant agent and administering a cytotoxic agent having a targeting means to the Lewis Y glycoproteins.

Abstract: Antibodies useful for and methods of treating LFA-1 alpha subunit associated physiological conditions and diseases treatable with an antibody that binds LFA-1 alpha subunit, such as HIV, are provided.

Abstract: The invention provides compositions and methods for cell separation. These reagents and techniques specifically agglutinate cells via surface antigen recognition and can be used to recover even rare cell types in high yield.

Abstract: This invention provides a composition which comprises an admixture of two compounds, wherein one compound retards attachment of HIV-1 to a CD4+ cell by retarding binding of HIV-1 gp120 envelope glycoprotein to CD4 on the surface of the CD4+ cell and the other compound retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate, wherein the relative mass ratio of the compounds in the admixture ranges from about 100:1 to about 1:100, the composition being effective to inhibit HIV-1 infection of the CD4+ cell. This invention also provides a method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with an amount of the above composition effective to inhibit HIV-1 infection of the CD4+ cell so as to thereby inhibit HIV-1 infection of the CD4+ cell.

Abstract: The present invention comprises and utilizes methods and compositions for treating hyperimmune reactions in the eye. Compositions comprising antibodies to gamma interferon alone and in combination with antibodies to TNF alpha and other drugs are described. Also disclosed in the invention are methods of applying a composition comprising interferon gamma antibodies and TNF alpha antibodies, alone and in combination, topically to the eye to treat hyperimmune reactions, such as transplant rejection, autoimmune diseases of the eye, and ocular disorders incidental to or connected with autoimmune diseases.

Abstract: The present invention relates to the discovery of a var gene and corresponding protein that modulates adhesion of parasitized red blood cells to chondroitin sulfate A. Novel biological tools, prophylactics, therapeutics, diagnostics, and methods of use of the foregoing are also disclosed.

Abstract: The inventor has determined that the nucleocapsid protein from a hepatitis virus can induce the prothrombinase, fgl2. The inventor has further developed that LF-A1 also induces fgl-2. This allows for the development of therapeutic methods and compositions for modulating immune coagulation. In particular, inhibitors of the N-protein or gene or LF-AL protein gene, or LF-A1 binding site on the fgl-2 promoter may be useful in inhibiting immune coagulation caused by a virus such as a hepatitis virus.

Abstract: Treating humans and animals intoxicated with a bacterial toxin by administration of antitoxin. Avian antitoxin in an aqueous solution in therapeutic amount that is orally administrable.

Abstract: The present invention provides attenuated live cultures of the pathogenic protozoan parasite, Neospora, and live vaccines against neosporosis prepared therefrom which are useful in the prevention of clinical disease and abortion in mammals.

Abstract: The present invention relates to compositions and methods for orally delivering antigens. The antigen and an adjuvant are combined with an acylated amino acid or polyamino acid and, a sulfonated amino acids or polyamino acid, or a salt of the foregoing.

Abstract: The recombinant production of Gap4, a chimeric GapC plasmin binding protein comprising the entire amino acid sequence of the Streptococcus dysgalactiae GapC protein in addition to unique amino acid sequences from the Streptococcus parauberis and Streptococcus agalactiae GapC proteins, is described. Also described is the use of Gap4 chimeric GapC protein in vaccine compositions to prevent or treat streptococcal infections in general and mastitis in particular.

Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-strucutral polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.

Abstract: Methods for treating fibromyalgia by administering a therapeutically effective amount of a botulinum toxin to a patient with fibromyalgia.

Abstract: Novel vaccines for use against &bgr;-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against &bgr;-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.

Abstract: The present invention relates to a controlled release system comprising matrix compositions which control the lag time and release rate of the composition, as well as pharmaceutical and other active ingredients included in the composition, through surface dissolution and/or bulk erosion of the system. The controlled release system can be used to target and control the release of active ingredients onto certain regions of the gastrointestinal tract including the stomach and the small intestine. The matrix compositions of the present invention can be comprised of the following components: a wax material, fat material, water sensitive material and surface active material.

Abstract: This composition is a topical admixture of submicron vitamin C in percentages of 40.001%-70% by weight with exceptional biological activity, and exhibiting deep transdermal penetration.

Abstract: A cosmetic treatment process is provided herein useful for reducing fine lines, wrinkles, or fine lines and wrinkles. The process comprises contacting a composition to an area of the skin or tissue of a subject, wherein the composition comprises a substance encapsulated within a lipid vesicle comprising a lipid having one or more polyethylene glycol (PEG) chains. The lipid vesicle has a charged surface, and an electric voltage is applied directly to the area of the skin that is contacted with the composition, whereby fine lines, wrinkles, or fine lines and wrinkles are reduced.

Abstract: The present invention relates to a new retinyl retinoate, a process for preparing same, a new intermediate which is useful for preparing same, and a cosmetic composition comprising the retinyl retinoate as the active ingredient.

Abstract: The present invention includes a method of manufacturing an article of manufacture comprising the steps of manufacturing a fabric softener and, including an amount of an insect repellent as a component of the fabric softener. The invention also includes a method of imparting insect repellence to an article comprising the step of adding an amount of insect repellent to an article within a washing machine during a rinse cycle. In one exemplary embodiment, the present invention utilizes DEET, N,N-diethyl-m-toluamide, as the insect repellent.

Abstract: Composition for combating insects, mites, ticks and parasites, said composition comprising at least as active agent coated siliceous containing particles, said particles having an average primary particle size of less than 100 nm, advantageously of less than 50 nm, preferably comprised between 10 and 40 nm, whereby the coating is a hydrophobic silicon containing coating

Abstract: An ant proof device includes an annular grooved body and a talcum powder product. The annular grooved body has a bottom face, an inner circumferential wall and an outer circumferential wall that form a receptacle. The nontoxic talcum powder product is contained in the receptacle for preventing ants from crawling through the annular grooved body. The talcum powder product is not volatile so that it is unnecessary to frequently supplement the talcum powder product. Also, children or pets will not accidentally get toxic. Its structure is simple and can be manufactured at low cost. A dustproof lid can be used with the ant proof device to prevent dust or water from dropping onto the surface of the talcum powder product.

Abstract: The present invention provides an environmentally compatible, pesticidal composition and method for the control of insect pests. The composition includes two components. The first component is a chelating agent, a metal complex of a chelating agent, and mixtures thereof, and the second component is preferably a carrier material.

Abstract: The present invention discloses a structural and mechanical model and modeling methods for human bone based on bone's hierarchical structure and on its hierarchical mechanical behavior. The model allows for the assessment of bone deformations, computation of strains and stresses due to the specific forces acting on bone during function, and contemplates forces that do or do not cause viscous effects and forces that cause either elastic or plastic bone deformation.

Abstract: The present invention is directed to an improved sustained release drug delivery device comprising a drug core, a unitary cup, and a permeable plug.

Abstract: An expandable stent suitable for implantation in a lumen is covered with a biological material. In one embodiment, biological fibers are interwoven to form a stent covering. The fibers are disposed at an angle with respect to the longitudinal axis of the stent so that when the stent is expanded, the angle increases. In another embodiment, a strip of pericardium is helically wound around a supporting stent while the stent is in a compressed state. When the stent is expanded, the strip unwinds, but maintains full coverage of the stent. Interlocking edges may be formed on the strip of pericardium to maintain full coverage of the stent.

Abstract: A composite material comprising an inorganic filler material and a oriented fibrous polymeric material characterised in that the fibrous material has areas of adjacent fibres fused together to form a network or continuous matrix while retaining oriented fibrous structure in the composite.